Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
about
Deferasirox for managing iron overload in people with thalassaemiaEvaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusionsProfile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesMedical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Treating thalassemia major-related iron overload: the role of deferiprone.An update on iron chelation therapyKinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasCombined chelation therapy with deferasirox and deferoxamine in thalassemia.An update on disordered iron metabolism and iron overload.Deferasirox: pharmacokinetics and clinical experience.Labile iron in cells and body fluids: physiology, pathology, and pharmacology.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.Deferasirox for managing iron overload in people with thalassaemia.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.Iron chelation in thalassemia: time to reconsider our comfort zones.Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Recent advances in β-thalassemiasUpdate on the use of deferasirox in the management of iron overload.Iron chelation therapy in thalassemia syndromesRelationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.The palatability and tolerability of deferasirox taken with different beverages or foods.The role of anaemia in oxidative and genotoxic damage in transfused β-thalassaemic patients.Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantationDeferasirox: Over a Decade of Experience in Thalassemia
P2860
Q24203718-E99DFDA8-2C38-4189-8D93-BE72BEF9EFFAQ26765306-107F7038-17F2-43B2-8CB7-CF9EEF1336EBQ26771519-D17295AE-8441-4DD7-B2C0-675FA2814252Q33420358-7B795C45-E038-41D9-95AA-A4EA24B0A64EQ35589756-81B924BE-0A6D-4896-91F4-96CB9BFC0FBDQ36344669-914D27CE-FE01-4D06-AD12-1843CD38E1B6Q36393446-4CB89799-F107-4637-A032-F253915AC639Q36439892-C3455818-4C0A-4A0F-AFE8-6F6CFE55F435Q36569047-5414C359-7FB9-4330-B044-6C08C78F1C75Q36670257-8C6DD8DA-8565-4733-8180-3EE029CD73C2Q37791615-F48D2A95-A13F-4036-B408-7015F3744305Q37969225-6309C399-27D0-4261-AC65-A869F053F69CQ38198634-6622E352-105F-44BD-A037-3A34BC2DE44BQ38219588-DB7B97BC-DA58-45CD-80AF-6218E8DB0C6CQ38226394-51A7AA8C-BE4A-4E9D-AEE8-33774B92D2DBQ38416115-F7EE8282-7FA0-40FD-8250-1BABF4A4F2AAQ38624033-92E22041-47F3-46A5-A0F1-C4BBBB2D4D24Q38962101-EB0280B6-8494-47AE-8B10-8061CD2E2FCAQ39782885-7B5CBC28-E342-4798-8940-85C3E21691E7Q41687355-77372A2B-0C6D-4B80-98A0-21F16C5D5D31Q41973193-55C56874-9C2B-41DF-BE5A-6520CE93E8D8Q42117340-74CA8842-1A49-4EA3-AA03-8BA09E040332Q42588949-498C2B88-AD53-4418-A7A4-3DB154D9F265Q42783336-3A76E03E-BFAE-4EFE-9EE2-B2C149E77872Q45271678-DCCE9075-BC96-4589-953C-CFC4D8A65218Q46466632-12A7A1F5-8E68-4475-9502-5DC1B0C0D130Q51123803-96568D16-11B8-4F6F-A882-7B5EAD2B2214Q57515058-DBD34F8A-76A3-4F5B-BEDF-DE7799C2824EQ58701123-CA8C055B-0353-41D8-8B7D-7BED7BFDFF81
P2860
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduction in labile plasma iro ...... atients with beta-thalassaemia
@en
Reduction in labile plasma iro ...... tients with beta-thalassaemia.
@nl
type
label
Reduction in labile plasma iro ...... atients with beta-thalassaemia
@en
Reduction in labile plasma iro ...... tients with beta-thalassaemia.
@nl
prefLabel
Reduction in labile plasma iro ...... atients with beta-thalassaemia
@en
Reduction in labile plasma iro ...... tients with beta-thalassaemia.
@nl
P2093
P2860
P1476
Reduction in labile plasma iro ...... atients with beta-thalassaemia
@en
P2093
Abdel Hmissi
Hanspeter Nick
Shahina Daar
Ulrike Kriemler-Krahn
P2860
P304
P356
10.1111/J.1600-0609.2008.01204.X
P577
2008-12-22T00:00:00Z